Sonus settles class action suit
Sonus Pharmaceuticals has settled a class action suit brought against it in a California Superior Court. The litigation, filed in San Diego, claimed that the company did not communicate clearly about the status of the Food and Drug Administration’s
Sonus Pharmaceuticals has settled a class action suit brought against it in a California Superior Court. The litigation, filed in San Diego, claimed that the company did not communicate clearly about the status of the Food and Drug Administrations clearance of EchoGen, the companys ultrasound contrast agent. Although Bothell, WA-based Sonus believes that the complaint was without merit, it chose to settle rather than engage in the litigation. Terms of the settlement were not disclosed, although Sonus did state that the terms were not monetary.
On the EchoGen front, at the end of September Sonus filed a complete response to conditions outlined in the FDAs approvable letter, which the company received in April (SCAN 4/28/99). Sonus believes that it has provided sufficient answer to the agencys letter, and continues to wait for its response, according to Greg Sessler, CFO.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
